Overview
SynaptixBio is a rare disease biotech company that is pioneering ground-breaking treatments for severe leukodystrophies and other childhood neurodegenerative diseases.
SynaptixBio’s mission is to deliver gene therapies for fatal leukodystrophies in children caused by loss of function or mutation in a single gene. Using a breadth of platforms including antisense oligonucleotide (ASO)-based technology, we can silence the expression of the toxic gene to reverse disease progression. This approach will create life saving treatments for severe genetic diseases that affect the central nervous system.
Company Details
- Employees
- 5
- Founded
- -
- Address
- Oxford , Oxfordshire, Gb
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.synaptixbio.com
- Keywords
- Pharmaceutical, Biotech, Leukodystrophy, Rare Disease, H-ABC, Hypomyelination, Basal Ganglia, Cerebrllum, Neurology, Brain, Preclincal, Drug Discovery, Life Sciences, Development, Paediatric Disorders.
- HQ
- Oxford , Oxfordshire
Synaptixbio Ltd. Questions
Synaptixbio Ltd.'s website is http://www.synaptixbio.com
Synaptixbio Ltd.'s LinkedIn profile is https://uk.linkedin.com/company/synaptixbio
Synaptixbio Ltd. has
5 employees.
View email and phone details for 5
employees at Synaptixbio Ltd..
Synaptixbio Ltd.'s industry is
Biotechnology Research
Synaptixbio Ltd.'s top competitors are
Accession Therapeutics Limited,
Barinthus Biotherapeutics,
Theolytics,
Greywolf Therapeutics,
Immunocore,
Adaptimmune,
Enara Bio,
Etcembly Ltd,
T-Cypher Bio,
Akamis Bio.
Synaptixbio Ltd.'s categories are Biotechnology Research
Synaptixbio Ltd.'s founding year is 2021
